Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Eli Lilly also agreed to acquire Organovo Holdings' (ONVO) clinical drug development program targeting farnesoid X receptor agonists. In its fourth-quarter, Eli Lilly results exceeded Wall Street ...

Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Organovo Hol ...

Eli Lilly (LLY) on Wednesday outlined a plan to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the US. The pharmaceutical giant said that three of the planned ...

Onvo Stock- Organovo's stock jumps 200% after Eli Lilly acquires its FXR program, including the promising IBD treatment ...

SAN DIEGO, CA, USA I5, 2025 I Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Eli Lilly (NYSE:LLY) announced plans to more than double its investments in domestic medicine production to over $50B on ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...